Effects of ethyl lauroyl arginine nasal spray on COVID-19
Phase 3
Completed
- Conditions
- COVID-19 (SARS-CoV-2 infection)Infections and Infestations
- Registration Number
- ISRCTN17834262
- Lead Sponsor
- Salvacion LLC
- Brief Summary
2022 Preprint results in https://doi.org/10.21203/rs.3.rs-1432140/v1 (added 09/08/2022)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
1. Signed informed consent
2. Confirmed for Covid-19 infection by RT-PCR tests
Exclusion Criteria
1. Allergy to ELAH
2. Females who were breast feeding or lactating
3. History of severe respiratory infections
4. Have received period Covid treatment
5. Participated in any interventional drug trial in previous 30 days
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <br> 1. Viral load measured using RT-PCR test post treatment (day 6)<br> 2. Number of Covid-19 free subjects measured using RT-PCR test post treatment (day 6)<br>
- Secondary Outcome Measures
Name Time Method Safety and tolerability of Covixyl-V LAEH nasal spray were assessed by evaluating AEs, serious adverse events (SAEs), vital signs, treatment discontinuation due to AEs, and nasal and physical examinations using patient records at the end of the study